德国转移性去势抵抗性前列腺癌二线和三线治疗中177Lu-PSMA-617放射配体疗法的成本-效用分析
该研究构建队列状态转移模型,评估德国mCRPC患者中177Lu-PSMA-617放射配体疗法(PRLT)的成本-效用。模型I显示三线PRLT联合标准治疗较单纯标准治疗每患者增量成本€27,200、增益0.39质量调整生命年(QALY),ICER为€69,418/QALY;模型II显示二线PRLT较卡巴他赛化疗每患者节省€1,460且增益0.11 QALY,为优势方案。作者认为PRLT作为二线或三线治疗具有成本效果。
要点
- 三线PRLT联合标准治疗较单纯标准治疗:增量成本€27,200/患者,增益0.39 QALY,ICER €69,418/QALY。
- 二线PRLT较卡巴他赛化疗:节省€1,460/患者,增益0.11 QALY,为优势方案。
- 作者认为PRLT作为mCRPC二线或三线治疗具有成本效果。
核心结论
- 德国虽无明确的支付意愿阈值来解释模型I的ICER,但该ICER落在其他已报销癌症疗法的范围内,作者认为PRLT作为mCRPC二线或三线治疗具有成本效果。
研究设计与样本
- 研究构建了两个队列状态转移模型:模型I含四个健康状态(治疗、治疗后稳定、进展、死亡),模型II含六个健康状态(治疗、治疗后稳定、进展后三线治疗、三线治疗后稳定、再次进展、死亡)。
- 转移概率来源于VISION和TheraP试验,生活质量数据来源于VISION和CARD试验,成本来源于法定健康保险理赔数据(2019-2022年)。
- 模型模拟五年时间 horizon,周期为一个月,应用周期内校正和3%贴现率,并进行敏感性分析。
主要发现
- 模型I中,PRLT联合标准治疗较单纯标准治疗每患者增量成本为€27,200,增益0.39 QALY,ICER为€69,418/QALY。
- 模型II中,PRLT联合标准治疗较卡巴他赛化疗每患者节省€1,460,增益0.11 QALY,为优势方案。
关键数值与推荐
- 模型I:PRLT联合标准治疗 vs 单纯标准治疗,增量成本€27,200/患者,增益0.39 QALY,ICER €69,418/QALY。
- 模型II:PRLT联合标准治疗 vs 卡巴他赛化疗,节省€1,460/患者,增益0.11 QALY。
临床怎么用
- 作者认为PRLT作为mCRPC二线或三线治疗具有成本效果。
局限性
- 2019至2022年间医院主要使用自产177Lu-PSMA-617,其成本低于目前市售产品,限制了研究结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the cost-effectiveness of 177Lu-PSMA-617 radioligand therapy (PRLT) in metastatic castration-resistant prostate cancer (mCRPC) in Germany by comparing (I) PRLT plus standard-of-care (SoC) versus SoC alone as third-line treatment and (II) PRLT versus second-line cabazitaxel chemotherapy. METHODS: Cohort state-transition models were developed with (I) four health states (treatment, stable after treatment, progression, death) and (II) six health states (treatment, stable after treatment, third-line treatment after progression, stable after third-line treatment, next progression, death). Transition probabilities were derived from the VISION and TheraP trials, and quality-of-life data from the VISION and CARD trials. Costs were derived from statutory health insurance claims data (2019-2022). Models simulated a five-year horizon with one-month cycles, applying within-cycle correction and a 3% discount rate. Sensitivity analyses addressed uncertainty. RESULTS: For Model I, PRLT plus SoC compared to SoC incurred incremental costs of €27,200 per patient, with a gain of 0.39 quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) of €69,418 per QALY gained. In Model II, PRLT plus SoC compared to cabazitaxel achieved incremental savings of €1,460 per patient and a QALY gain of 0.11, making it the dominant option. CONCLUSION: Although Germany lacks an explicit willingness-to-pay threshold for interpreting the ICER of Model I, it falls within the range of other reimbursed cancer therapies. This suggests PRLT is cost-effective as second- or third-line treatment for mCRPC. Between 2019 and 2022, hospitals mainly used self-produced 177Lu-PSMA-617, which was less costly than the product now commercially available, limiting the generalizability of our findings.
引用
- Brinkmann C, Baum RP, Stargardt T, et al. Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany. Eur J Nucl Med Mol Imaging. 2025. PMID: 40338306. doi:10.1007/s00259-025-07317-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。